Sequent Scientific Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company.

Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.

Powered by Capital Market - Live News

Net profit of Sequent Scientific reported to Rs 2.61 crore in the quarter ended September 2024 as against net loss of Rs 8.38 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 368.65 crore in the quarter ended September 2024 as against Rs 345.97 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Sequent Scientific will hold a meeting of the Board of Directors of the Company on 13 November 2024

Powered by Capital Market - Live News

Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020.

Powered by Capital Market - Live News